Meeting
2021 ASCO Annual Meeting
Chemoimmunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in patients with an Eastern Cooperative Group (ECOG) performance status (PS) of two or greater.
Authors
Daniel Almquist
Mayo Clinic, Phoenix, AZ
Daniel Almquist , Blake Langlais , Nathan Y Yu , Terence Tai Weng Sio , Panos Savvides , Ping Yang , Steven E. Schild , Aaron Scott Mansfield , Vinicius Ernani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8569)
DOI
10.1200/JCO.2021.39.15_suppl.8569
Abstract #
8569
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Reconsidering the cutoff between sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.
First Author: Masahiro Torasawa
Poster
2023 ASCO Annual Meeting
Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.
First Author: Aditya Juloori
Poster
2023 ASCO Annual Meeting
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
First Author: Lionel Falchero
Poster
2024 ASCO Annual Meeting
DAREON-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC).
First Author: Solange Peters